Earnings

Celgene, which is being bought by Bristol-Myers Squibb, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.

Bristol-Myers agreed to buy Celgene for about $74 billion earlier this month, a deal that will expand its pipeline of cancer drugs as the company goes head-to-head against rival Merck & Co.

Sales of Celgene’s biggest drug Revlimid rose 16.5 percent to $2.55 billion in the fourth quarter, in line with analysts’ expectations, according to Refinitiv IBES estimates.

Otezla brought in revenue of $448 million in the quarter, about 21 percent higher than last year and well above the average analyst estimate of $430.2 million.

The drugmaker, which also reaffirmed its forecast for 2020, posted a net profit of $1.07 billion, or $1.50 per share, for the three months ended Dec. 31, compared with a loss of $81 million, or 10 cents per share, a year earlier, when it took a $1.21 billion charge related to the U.S. tax law overhaul.

Excluding one-time items, Celgene earned $2.39 per share, above estimates of $2.32 per share.

Total revenue rose nearly 16 percent to $4.04 billion, higher than the $3.99 billion analysts had expected.

Products You May Like

Articles You May Like

Nvidia jumps on earnings beat
Quail Lodge car show has become the hottest ticket for the super rich at Pebble Beach Concours
Greenspan says ‘there is no barrier’ to negative yields in the US
Stocks making the biggest moves after hours: RealReal, Tilray, and Myriad
Going by past market history, this comeback rally should peak by the middle of next week: Nomura

Leave a Reply

Your email address will not be published. Required fields are marked *